Last reviewed · How we verify
NCT04421846: COLETTE
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
NA trial testing Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3) in Status Epilepticus in 400 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 400 |
| Start date | 25 November 2020 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
- Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)
Conditions studied
- Status Epilepticus — all drugs for Status Epilepticus →
- Dysimmune Encephalopathy — all drugs for Dysimmune Encephalopathy →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
2 and older, any sex, with Status Epilepticus or Dysimmune Encephalopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04421846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Status Epilepticus
Currently open trials in the same condition.
- NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
- NCT06194747 — Improving Status Epilepticus Treatment Times · NA · recruiting
- NCT06017973 — The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus · NA · recruiting
- NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
- NCT05839418 — Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04421846 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 4 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04421846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing